Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer.

Xun-Xi LuZongchao GouHong ChenLi LiFei ChenChunjuan BaoHong Bu

Published in: Journal for immunotherapy of cancer (2024)

Our IP model shows favorable performance in predicting NACI response and is an effective tool for identifying BC patients who will benefit from ICIs. It may help clinicians optimize treatment strategies and guide clinical decision-making.

Keyphrases

decision making
rectal cancer
lymph node
palliative care
locally advanced
copy number
squamous cell carcinoma
dna methylation
radiation therapy
transcription factor
genome wide analysis